Literature DB >> 18729067

Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis.

E Ihse1, A Ybo, Ob Suhr, P Lindqvist, C Backman, P Westermark.   

Abstract

Swedish familial systemic amyloidosis with polyneuropathy (FAP) depends on a mutation leading to a methionine-for-valine substitution in transthyretin. The disease appears with different clinical manifestations, including age of onset and involvement of the heart. Liver transplantation is currently the only curative treatment, but progressive cardiomyopathy may occur post-transplant. Two amyloid deposition patterns have previously been described in the heart. In one, the amyloid consists partially of transthyretin fragments and is weakly stainable by Congo red, while in the other, only full-length molecules are found and the fibrils have a strong affinity for Congo red. The present study aimed to see whether these morphological and biochemical variations have clinical implications. Subcutaneous adipose tissue biopsies were taken from 33 patients with Val30Met FAP and examined by microscopy, electrophoresis and western blot. Clinical data included age, sex, duration of disease and echocardiographic determination of the interventricular septum (IVS) thickness. It was found that fibrils composed of only full-length transthyretin were associated with early age of onset (44.8 +/- 12.9 years), no clinical cardiac involvement and a strong affinity for Congo red. In contrast, presence of transthyretin fragments in the amyloid was associated with late age of onset (67.3 +/- 7.0 years), signs of cardiac involvement and weak Congo red staining. For each individual, the same molecular type of amyloid was found in different organs. This is the first report showing that variations in clinical appearance of familial ATTR amyloidosis are associated with specific structural differences in the amyloid fibrils, and therefore may have a molecular cause. The molecular type of amyloid can be determined from a subcutaneous fat tissue biopsy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18729067     DOI: 10.1002/path.2411

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  53 in total

Review 1.  [Amyloid and amyloidoses].

Authors:  C Röcken; M Eriksson
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

Review 2.  [Hereditary and non-hereditary cutaneous amyloidoses].

Authors:  S Schreml; J Schroeder; F Eder; R M Szeimies; M Landthaler; P Babilas
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

Review 3.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

4.  Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).

Authors:  Björn Pilebro; Sandra Arvidsson; Per Lindqvist; Torbjörn Sundström; Per Westermark; Gunnar Antoni; Ole Suhr; Jens Sörensen
Journal:  J Nucl Cardiol       Date:  2016-09-19       Impact factor: 5.952

Review 5.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

6.  Pathogenic Mutations Induce Partial Structural Changes in the Native β-Sheet Structure of Transthyretin and Accelerate Aggregation.

Authors:  Kwang Hun Lim; Anvesh K R Dasari; Renze Ma; Ivan Hung; Zhehong Gan; Jeffery W Kelly; Michael C Fitzgerald
Journal:  Biochemistry       Date:  2017-08-30       Impact factor: 3.162

7.  A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.

Authors:  Mitsuharu Ueda; Masamitsu Okada; Mineyuki Mizuguchi; Barbara Kluve-Beckerman; Kyosuke Kanenawa; Aito Isoguchi; Yohei Misumi; Masayoshi Tasaki; Akihiko Ueda; Akinori Kanai; Ryoko Sasaki; Teruaki Masuda; Yasuteru Inoue; Toshiya Nomura; Satoru Shinriki; Tsuyoshi Shuto; Hirofumi Kai; Taro Yamashita; Hirotaka Matsui; Merrill D Benson; Yukio Ando
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 8.  Novel drugs targeting transthyretin amyloidosis.

Authors:  Mazen Hanna
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 9.  Currents concepts on the immunopathology of amyloidosis.

Authors:  Anupama Bhat; Carlo Selmi; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 10.  Targeting protein aggregation for the treatment of degenerative diseases.

Authors:  Yvonne S Eisele; Cecilia Monteiro; Colleen Fearns; Sandra E Encalada; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.